Bone repair assessment of critical size defects in rats treated with mineralized bovine bone (Bio-Oss®) and photobiomodulation therapy: a histomorphometric and immunohistochemical study

Letícia Cavassini Torquato, Eduardo Antonio Chelin Suárez, Daniella Viscensotto Bernardo, Isis Luzcybel Ribeiro Pinto, Ludmilla Oliveira Mantovani, Thiago Igor Lemes Silva, Maria Aparecida Neves Jardini, Mauro Pedrine Santamaria, Andrea Carvalho De Marco

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Abstract

This study aimed to investigate the effects of administering photobiomodulation therapy (PBM) with bovine bone matrix on critical size defects in rats. Seventy-two adult male rats (albinus, Wistar), 90 days old, were used. Defect of 5 mm in diameter was made in their calvaria. The animals were divided into 4 groups: C-blood clot, B-Bio-Oss®, L-PBM, B+L-Bio-Oss®+PBM. Each group has been subdivided into 07, 30, and 60 days of observation. For PBM, a low GaAlAs energy of 660 nm was irradiated, total energy density of 45 J/cm2. PBM was conducted in a trans-surgical form once only. For immunohistochemistry, a semi-quantitative analysis was made of expression of osteoprotegerin (OPG), nuclear kappa B-factor ligand receptor activator (RANKL), and tartrate-resistant acid phosphatase (TRAP). All histomorphometric data were statistically analyzed by ANOVA and Tukey test, significance level of 5%. The groups that showed the highest proportion of neoformation were L (0.39% ± 0.13) and C (0.37% ± 0.97), but groups B and B+L had larger defect size (C-1.75 mm2 ± 0.40, B-3.02 mm2 ± 0.63, L-2.45 mm2 ± 0.53, B+L-3.23 mm2 ± 1.01). In immunohistochemistry, groups B and B+L had higher immunostaining scores for OPG and RANKL at 60 days, and TRAP immunostaining increased in all groups at 30 days, but group L was the only one to present specimens with score 0. Although, at 60 days, groups L and C presented the highest proportion of bone neoformation, at 30 days group B+L had more than twice as much bone neoformation as group B, the choice of treatment application should depend on the aim of the treatment.

Original languageEnglish
Pages (from-to)1515-1525
Number of pages11
JournalLasers in Medical Science
Volume36
Issue number7
DOIs
StatePublished - Sep 2021

Bibliographical note

Publisher Copyright:
© 2021, The Author(s), under exclusive licence to Springer-Verlag London Ltd. part of Springer Nature.

Keywords

  • Biocompatible materials
  • Bone regeneration
  • Bone transplantation
  • Immunohistochemistry
  • Low-level light therapy

ASJC Scopus subject areas

  • Surgery
  • Dermatology

Fingerprint

Dive into the research topics of 'Bone repair assessment of critical size defects in rats treated with mineralized bovine bone (Bio-Oss®) and photobiomodulation therapy: a histomorphometric and immunohistochemical study'. Together they form a unique fingerprint.

Cite this